Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, has filed a provisional patent application with the U.S. Patent and Trademark Office (“USPTO”) for its lead asset SPC-15, demonstrating its commitment to innovative treatments for stress-induced psychiatric disorders, including post-traumatic stress disorder (“PTSD”). The patent focuses on targeting N-methyl-D-aspartate receptors (“NMDARs”) and serotonin type IV receptors (“5-HT4Rs”) to address stress-related behaviors such as perseverative behavior and hyponeophagia. Licensed through a collaboration with Columbia University, SPC-15 is exclusively owned and globally controlled by Silo for development and commercialization. CEO Eric Weisblum stated that the filing underscores Silo’s robust intellectual property (“IP”) strategy and enhances its ability to deliver transformative therapies. SPC-15, an intranasal serotonin 5-HT4 receptor agonist, also holds promise for the U.S. Food and Drug Administration’s (“FDA”) expedited 505(b)(2) approval pathway, facilitating accelerated development for PTSD and anxiety treatment.
To view the full press release, visit https://ibn.fm/OemRr
About Silo Pharma Inc.
Silo Pharma is a developmental-stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions and central nervous system (“CNS”) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug-delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting post-traumatic stress disorder (“PTSD”) and stress-induced anxiety disorders. SP-26 is a time-release, ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (“MS”). Silo’s research and development programs are conducted through collaborations with universities and independent laboratories. For more information about the company, visit www.SiloPharma.com .
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
